Dicot's clinical phase 1 study starts today

Last week, Dicot received approval from the relevant authorities to start a clinical phase 1 trial. Dicot's partner CTC, which will conduct the study, began recruiting participants immediately. Since all other preparations were completed, the study can start today, just over a week after the approval. It commences with the first of two screening visits to identify participants for the study's first dose group. Screening is the process where research applicants are examined and selected based on a variety of study specific criteria.

As Dicot previously announced, this is a placebo-controlled phase 1 clinical trial with the primary objective to evaluate LIB-01's safety profile in humans. The trial is double-blind, meaning that neither clinic staff who administer the study drug, nor participants, know who is receiving LIB-01 and who is receiving placebo.

"We are proud and happy that everything has gone according to plan and that we were able to start so quickly after the approval from the authorities. Now a completely new chapter in the development of LIB-01 begins. We expect that the first results from the study can be presented during the spring of 2024," says Elin Trampe, CEO of Dicot.